Hexa Reports Market Research Reports and Insightful Company Profiles
Iguratimod, T-614 (Rheumatoid Arthritis) Global Share and Size, Growth and Overview, Forecast and Market Analysis to 2023
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Browse Detail Report With TOC @ http://www.hexareports.com/report/iguratimod-t-614rheumatoid-arthritis-forecast-and-market-analysis-to-2023/details
Iguratimod (T-614) was approved in Japan in June 2012, and was subsequently launched the following September for the treatment of adults with active RA as an add-on to MTX in patients who are not adequately controlled by monotherapy (Eisai, press release, September 11, 2012). It was also approved in China in 2012. Scope
Hexa Reports Market Research Reports and Insightful Company Profiles - Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Iguratimod/T-614 including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Iguratimod/T-614 for the top 2 countries from 2013 to 2023. - Sales information covered for Japan and China. Reasons To Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return. - Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. - Make more informed business decisions from insightful and in-depth analysis of Iguratimod/T-614 performance. - Obtain sales forecast for Iguratimod/T-614 from 2013-2023 in top 2 countries (Japan and China). Request A Sample copy of This Report @ http://www.hexareports.com/sample/42263
Table of Contents Table of Contents 6 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 9 2.1 Catalyst 9 2.2 Related Reports 10 2.3 Upcoming Related Reports 13 3 Disease Overview 14 3.1 Etiology and Pathophysiology 14 3.1.1 Etiology 14 3.1.2 Pathophysiology 14 3.2 Symptoms 19 3.3 Prognosis 20 3.4 Quality of Life 20 4 Disease Management 21 4.1 Diagnosis and Treatment Overview 21 4.1.1 Diagnosis 21 4.1.2 Treatment Guidelines 23 4.1.3 Leading Prescribed Drugs for the Treatment of RA 32
Hexa Reports Market Research Reports and Insightful Company Profiles 4.1.4 Clinical Practice 34 5 Competitive Assessment 39 5.1 Overview 39 6 Iguratimod/T-614 41 6.1 Overview 41 6.2 Efficacy 42 6.3 Safety 43 6.4 SWOT Analysis 43 6.5 Forecast 44 7 Appendix 45 7.1 Bibliography 45 7.2 Abbreviations 48 7.3 Methodology 51 7.4 Forecasting Methodology 51 7.4.1 Diagnosed RA Patients 51 7.4.2 Percentage of Drug-Treated Patients 52 7.4.3 General Pricing Assumptions 52 7.4.4 Individual Drug Assumptions 53 7.4.5 Generic and Biosimilar Erosion 53 7.5 Primary Research - KOLs Interviewed for This Report 54 7.6 Primary Research - Prescriber Survey 56 7.7 About the Authors 57 7.7.1 Analyst 57 7.7.2 Reviewer 57 7.7.3 Therapy Area Director 58 7.7.4 Global Head of Healthcare 58 7.8 About GlobalData 59 7.9 Disclaimer 59
Browse Full Report @ http://www.hexareports.com/report/iguratimod-t-614-rheumatoid-arthritisforecast-and-market-analysis-to-2023/details
About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Hexa Reports Market Research Reports and Insightful Company Profiles
Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: sales@hexareports.com Our Website: http://www.hexareports.com/ Visit Our Blogs: http://hexareports.blogspot.in